HDAC9 and peripheral T-cell lymphoma, not otherwise specified: Several HDAC inhibitors—romidepsin, vorinostat, and belinostat—are currently FDA-approved for treating hematologic malignancies such as multiple myeloma and peripheral T-cell lymphoma (91).